Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy

BMC Medical Genomics

Volumn 4, Issue , 2011, Pages

  Kemaladewi, Dwi U ^a   Hoogaars, Willem M H ^a   Van Heiningen, Sandra H ^a   Terlouw, Samuel ^a   De Gorter, David J J ^a,b   Den Dunnen, Johan T ^a   Van Ommen, Gert Jan B ^a   Aartsma Rus, Annemieke ^a   Ten Dijke, Peter ^a   T'Hoen, Peter A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; MESSENGER RNA; MYOGENIC FACTOR 5; MYOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHIN GENE; EXON; EXON SKIPPING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTATOR GENE; MYOSTATIN GENE; MYOTUBE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECT; GENETICS; METABOLISM; MUSCLE DEVELOPMENT; MYOBLAST; PATHOLOGY; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; DYSTROPHIN; EXONS; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED MDX; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; MYOSTATIN; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

EID: 79954570149     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-4-36     Document Type: Article

References (51)

1. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. AP Monaco CJ Bertelson S Liechti-Gallati H Moser LM Kunkel, Genomics 1988 2 90 95 10.1016/0888-7543(88)90113-9 3384440
2. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. A Aartsma-Rus JC van Deutekom IF Fokkema GJ van Ommen JT den Dunnen, Muscle Nerve 2006 34 135 144 10.1002/mus.20586 16770791 (Pubitemid 44167796)
3. Diagnosis and new treatments in muscular dystrophies. AY Manzur F Muntoni, J Neurol Neurosurg Psychiatry 2009 80 706 714 19531685
4. Gene therapy for muscular dystrophy: current progress and future prospects. C Trollet T Athanasopoulos L Popplewell A Malerba G Dickson, Expert Opinion on Biological Therapy 2009 9 849 866 10.1517/14712590903029164 19527108
5. The therapeutic potential of antisense-mediated exon skipping. GJ van Ommen JC van Deutekom A Aartsma-Rus, Curr Opin Mol Ther 2008 10 140 149 18386226 (Pubitemid 351498876)
6. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. A Aartsma-Rus M Bremmer-Bout AA Janson JT den Dunnen GJ van Ommen JC van Deutekom, Neuromuscul Disord 2002 12 Suppl 1 71 S77 12206800
7. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. A Aartsma-Rus AA Janson WE Kaman M Bremmer-Bout JT den Dunnen F Baas GJ van Ommen JC van Deutekom, Hum Mol Genet 2003 12 907 914 10.1093/hmg/ddg100 12668614 (Pubitemid 36504033)
8. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. A Aartsma-Rus AA Janson WE Kaman M Bremmer-Bout GJ van Ommen JT den Dunnen JC van Deutekom, Am J Hum Genet 2004 74 83 92 10.1086/381039 14681829 (Pubitemid 38085240)
9. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. CJ Mann K Honeyman G McClorey S Fletcher SD Wilton, J Gene Med 2002 4 644 654 10.1002/jgm.295 12439856 (Pubitemid 40277188)
10. Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. M Bremmer-Bout A Aartsma-Rus EJ de Meijer WE Kaman AA Janson RH Vossen GJ van Ommen JT den Dunnen JC van Deutekom, Mol Ther 2004 10 232 240 10.1016/j.ymthe.2004.05.031 15294170 (Pubitemid 39117869)
11. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. HA Heemskerk CL de Winter SJ de Kimpe P van Kuik-Romeijn N Heuvelmans GJ Platenburg GJ van Ommen JC van Deutekom A Aartsma-Rus, J Gene Med 2009 11 257 266 10.1002/jgm.1288 19140108
12. Local Dystrophin Restoration with Antisense Oligonucleotide PRO051. JC van Deutekom AA Janson IB Ginjaar WS Frankhuizen A Aartsma-Rus M Bremmer-Bout JT den Dunnen K Koop AJ van der Kooi NM Goemans SJ de Kimpe PF Ekhart EH Venneker GJ Platenburg JJ Verschuuren GJ van Ommen, N Engl J Med 2007 357 2677 2686 10.1056/NEJMoa073108 18160687
13. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. M Kinali V rechavala-Gomeza L Feng S Cirak D Hunt C Adkin M Guglieri E Ashton S Abbs P Nihoyannopoulos ME Garralda M Rutherford C McCulley L Popplewell IR Graham G Dickson MJ Wood DJ Wells SD Wilton R Kole V Straub K Bushby C Sewry JE Morgan F Muntoni, Lancet Neurol 2009 8 918 928 10.1016/S1474-4422(09)70211-X 19713152
14. Cell heterogeneity upon myogenic differentiation: down-regulation of MyoD and Myf-5 generates 'reserve cells'. N Yoshida S Yoshida K Koishi K Masuda Y Nabeshima, J Cell Sci 1998 111 769 779 9472005 (Pubitemid 28163885)
15. Myogenic satellite cells: physiology to molecular biology. TJ Hawke DJ Garry, J Appl Physiol 2001 91 534 551 11457764 (Pubitemid 32681081)
16. Evidence for defective myoblasts in Duchenne muscular dystrophy. HM Blau C Webster GK Pavlath CP Chiu, Adv Exp Med Biol 1985 182 85 110 4003170
17. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. A Clop F Marcq H Takeda D Pirottin X Tordoir B Bibe J Bouix F Caiment JM Elsen F Eychenne C Larzul E Laville F Meish D Milenkovic J Tobin C Charlier M Georges, Nat Genet 2006 38 813 818 10.1038/ng1810 16751773 (Pubitemid 43980603)
18. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. AC McPherron AM Lawler SJ Lee, Nature 1997 387 83 90 10.1038/387083a0 9139826 (Pubitemid 27202654)
19. Double muscling in cattle due to mutations in the myostatin gene. AC McPherron SJ Lee, Proc Natl Acad Sci USA 1997 94 12457 12461 10.1073/pnas.94.23.12457 9356471 (Pubitemid 27492550)
20. Myostatin mutation associated with gross muscle hypertrophy in a child. M Schuelke KR Wagner LE Stolz C Hubner T Riebel W Komen T Braun JF Tobin SJ Lee, N Engl J Med 2004 350 2682 2688 10.1056/NEJMoa040933 15215484 (Pubitemid 38788003)
21. Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. GD Shelton E Engvall, Neuromuscul Disord 2007 17 721 722 10.1016/j.nmd.2007.06.008 17651971 (Pubitemid 47362683)
22. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. A Rebbapragada H Benchabane JL Wrana AJ Celeste L Attisano, Mol Cell Biol 2003 23 7230 7242 10.1128/MCB.23.20.7230- 7242.2003 14517293 (Pubitemid 37211004)
23. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. B Langley M Thomas A Bishop M Sharma S Gilmour R Kambadur, J Biol Chem 2002 277 49831 49840 10.1074/jbc.M204291200 12244043 (Pubitemid 36014431)
24. Myostatin signals through Pax7 to regulate satellite cell self-renewal. C McFarlane A Hennebry M Thomas E Plummer N Ling M Sharma R Kambadur, Experimental Cell Research 2008 314 317 329 10.1016/j.yexcr.2007.09.012 17949710 (Pubitemid 350225602)
25. Myostatin Regulates Cell Survival during C2C12 Myogenesis. R Rios I Carneiro VM Arce J Devesa, Biochemical and Biophysical Research Communications 2001 280 561 566 10.1006/bbrc.2000.4159 11162556 (Pubitemid 32912828)
26. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. WE Taylor S Bhasin J Artaza F Byhower M Azam DH Willard Jr FC Kull Jr N Gonzalez-Cadavid, Am J Physiol Endocrinol Metab 2001 280 221 E228 11158924
27. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. M Thomas B Langley C Berry M Sharma S Kirk J Bass R Kambadur, J Biol Chem 2000 275 40235 40243 10.1074/jbc.M004356200 10976104 (Pubitemid 32064654)
28. Functional improvement of dystrophic muscle by myostatin blockade. S Bogdanovich TO Krag ER Barton LD Morris LA Whittemore RS Ahima TS Khurana, Nature 2002 420 418 421 10.1038/nature01154 12459784 (Pubitemid 35415652)
29. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. LS Krivickas R Walsh AA Amato, Muscle Nerve 2009 39 3 9 10.1002/mus.21200 19086063
30. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. KR Wagner JL Fleckenstein AA Amato RJ Barohn K Bushby DM Escolar KM Flanigan A Pestronk R Tawil GI Wolfe M Eagle JM Florence WM King S Pandya V Straub P Juneau K Meyers C Csimma T Araujo R Allen SA Parsons JM Wozney ER Lavallie JR Mendell, Ann Neurol 2008 63 561 571 10.1002/ana.21338 18335515
31. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. S Bogdanovich KJ Perkins TO Krag LA Whittemore TS Khurana, FASEB J 2005 19 543 549 10.1096/fj.04-2796com 15791004 (Pubitemid 40471245)
32. Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. A Matsakas K Foster A Otto R Macharia MI Elashry S Feist I Graham H Foster P Yaworsky F Walsh G Dickson K Patel, Neuromuscul Disord 2009 19 489 499 10.1016/j.nmd.2009.06.367 19541486
33. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. C Qiao J Li J Jiang X Zhu B Wang J Li X Xiao, Hum Gene Ther 2008 19 241 254 10.1089/hum.2007.159 18288893
34. Coordinated patterns of gene expression for adult muscle build-up in transgenic mice expressing myostatin propeptide. B Zhao EJ Li RJ Wall J Yang, BMC Genomics 2009 10 305 10.1186/1471-2164-10-305 19586544
35. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. SJ Lee LA Reed MV Davies S Girgenrath ME Goad KN Tomkinson JF Wright C Barker G Ehrmantraut J Holmstrom B Trowell B Gertz MS Jiang SM Sebald M Matzuk E Li LF Liang E Quattlebaum RL Stotish NM Wolfman, Proc Natl Acad Sci USA 2005 102 18117 18122 10.1073/pnas.0505996102 16330774 (Pubitemid 41798511)
36. Myostatin directly regulates skeletal muscle fibrosis. ZB Li HD Kollias KR Wagner, J Biol Chem 2008 283 19371 19378 10.1074/jbc.M802585200 18453534
37. Combination of Myostatin Pathway Interference and Dystrophin Rescue Enhances Tetanic and Specific Force in Dystrophic mdx Mice. J Dumonceaux S Marie C Beley C Trollet A Vignaud A Ferry G Butler-Browne L Garcia, Mol Ther 2010
38. AAV-directed muscular dystrophy gene therapy. Y Tang J Cummins J Huard B Wang, Expert Opin Biol Ther 2010 10 395 408 10.1517/14712591003604690 20132060
39. RNA-targeting approaches for neuromuscular diseases. RF Le K Charton CL Lorson I Richard, Trends Mol Med 2009 15 580 591 10.1016/j.molmed.2009.10.005 19906562
40. Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. CM Liu Z Yang CW Liu R Wang P Tien R Dale LQ Sun, Gene Ther 2008 15 155 160 10.1038/sj.gt.3303016 18033313 (Pubitemid 351150039)
41. Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. TR Magee JN Artaza MG Ferrini D Vernet FI Zuniga L Cantini S Reisz-Porszasz J Rajfer NF Gonzalez-Cadavid, J Gene Med 2006 8 1171 1181 10.1002/jgm.946 16810717 (Pubitemid 44480408)
42. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. A Aartsma-Rus AA Janson WE Kaman M Bremmer-Bout JT den Dunnen F Baas GJ van Ommen JC van Deutekom, Hum Mol Genet 2003 12 907 914 10.1093/hmg/ddg100 12668614 (Pubitemid 36504033)
43. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. CH Zhu V Mouly RN Cooper K Mamchaoui A Bigot JW Shay JP Di Santo GS Butler-Browne WE Wright, aging cell 2007 6 515 523 10.1111/j.1474-9726.2007.00306.x 17559502 (Pubitemid 47087056)
44. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. A Aartsma-Rus L van Vliet M Hirschi AA Janson H Heemskerk CL de Winter S de Kimpe JC van Deutekom PA 't Hoen GJ van Ommen, Mol Ther 2009 17 548 553 10.1038/mt.2008.205 18813282
45. Myostatin imposes reversible quiescence on embryonic muscle precursors. H Amthor A Otto R Macharia I McKinnell K Patel, Dev Dyn 2006 235 672 680 10.1002/dvdy.20680 16425219
46. Myostatin negatively regulates satellite cell activation and self-renewal. S McCroskery M Thomas L Maxwell M Sharma R Kambadur, J Cell Biol 2003 162 1135 1147 10.1083/jcb.200207056 12963705 (Pubitemid 37174195)
47. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. A Aartsma-Rus CL de Winter AA Janson WE Kaman GJ van Ommen JT den Dunnen JC van Deutekom, Oligonucleotides 2005 15 284 297 10.1089/oli.2005.15.284 16396622 (Pubitemid 43108225)
48. RNA secondary structure prediction. DH Mathews DH Turner M Zuker, Curr Protoc Nucleic Acid Chem 2007 Chapter 11 Unit 11.2
49. Antisense-induced Myostatin Exon Skipping Leads to Muscle Hypertrophy in Mice Following Octa guanidine Morpholino Oligomer Treatment. JK Kang A Malerba L Popplewell K Foster G Dickson, Mol Ther 2010
50. Quadrupling Muscle Mass in Mice by Targeting TGF- Signaling Pathways. SJ Lee, PLoS ONE 2007 2 789 10.1371/journal.pone.0000789 17726519
51. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. TA Souza X Chen Y Guo P Sava J Zhang JJ Hill PJ Yaworsky Y Qiu, Mol Endocrinol 2008 22 2689 2702 10.1210/me.2008-0290 18927237